
产品介绍 评论(0)
物种
Human分子别名
PCN, PLTN, Plectin-1, PLEC1Accession
Q15149-1表达序列
Ala4377-Ala4684 with His Tag at the N-Terminus
表达宿主
HEK293分子量
40-60kDa (Reducing)
纯度
>90% by SDS-PAGE标记
Unconjugated标签
His Tag性状
Lyophilized Powder缓冲体系
PBS, pH7.4, 5% trehalose
溶解方法
Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
储存条件
· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
· 3 months, -20 to -80℃ under sterile conditions after reconstitution.
· 1 week, 2 to 8℃ under sterile conditions after reconstitution.
· Please avoid repeated freeze-thaw cycles.文献引用
1.Smith FJ, Eady RA, Leigh IM, McMillan JR, Rugg EL, Kelsell DP, Bryant SP, Spurr NK, Geddes JF, Kirtschig G, Milana G, de Bono AG, Owaribe K, Wiche G, Pulkkinen L, Uitto J, McLean WH, Lane EB. Plectin deficiency results in muscular dystrophy with epidermolysis bullosa. Nat Genet. 1996 Aug;13(4):450-7.
2.McLean WH, Pulkkinen L, Smith FJ, Rugg EL, Lane EB, Bullrich F, Burgeson RE, Amano S, Hudson DL, Owaribe K, McGrath JA, McMillan JR, Eady RA, Leigh IM, Christiano AM, Uitto J. Loss of plectin causes epidermolysis bullosa with muscular dystrophy: cDNA cloning and genomic organization. Genes Dev. 1996 Jul 15;10(14):1724-35.
Plectin is a large cytolinker protein composed of an N-terminal actin-binding domain, a central rod-shaped α-helical coiled-coil region, and a C-terminal intermediate filament-binding domain, with multiple alternatively spliced isoforms enabling diverse subcellular localization; its functional core lies in bridging microfilaments, intermediate filaments, and microtubule networks to maintain cellular mechanical stability, while also participating in hemidesmosome assembly, myofibril integrity maintenance, and signal transduction regulation. Clinically, PLEC gene mutations cause epidermolysis bullosa simplex (EBS) and its variant subtypes with muscular dystrophy, pyloric atresia, or cardiomyopathy, collectively termed "plectinopathies," with pathological mechanisms involving dermal-epidermal junction disruption, desmin aggregation in muscle fibers, and mitochondrial dysfunction, while recent therapeutic strategies such as chemical chaperone approaches have provided new directions for treatment.
电泳
1μg (R: reducing condition).







评论(0)